Platelet Function on Abacavir and Tenofovir

University of California, Los Angeles (UCLA)

Status: Completed

Conditions: Platelet Aggregation, Spontaneous; Cardiovascular Diseases; HIV/AIDS

Treatments: Diagnostic Test: Platelet aggregation

Study type: Observational

Funder types: Other

Identifiers

NCT03081572

5P30A1028697

Details and patient eligibility

About

This is a small observational study aimed at observing differences in platelet function in HIV patients on abacavir versus tenofovir based anti-HIV drugs. There is some correlation between platelet activation and cardiovascular disease- this study will act as a pilot to see if platelet activation among abacavir users may explain the correlation between abacavir and cardiovascular disease in HIV positive patients.

This study will enroll 44 participants total; 22 on abacavir-based treatment, 22 on tenofovir-based treatment. There is only one study visit which includes a blood draw, physical assessment, and review of medical history.

Enrollment: 24 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• HIV positive
• Stable antiretroviral regimen for > 3months containing either abacavir or tenofovir
• Suppressed HIV viral load

Exclusion criteria

• Current cigarette smoking
• Pre-existing platelet disorder
• current or recent (last 6 months) antiplatelet therapy
• pregnancy

Trial design

24 participants in 2 patient groups

Abacavir Group

Description:

HIV positive individuals currently taking an abacavir based regimen

Treatment:

Diagnostic Test: Platelet aggregation

Tenofovir Group

Description:

HIV positive individuals currently taking a tenofovir based regime

Treatment:

Diagnostic Test: Platelet aggregation